Search details
1.
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
N Engl J Med
; 385(25): 2336-2347, 2021 12 16.
Article
in English
| MEDLINE | ID: mdl-34914339
2.
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.
J Natl Compr Canc Netw
; 21(6): 594-608, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37308117
3.
Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.
Oncologist
; 27(6): 441-446, 2022 06 08.
Article
in English
| MEDLINE | ID: mdl-35552450
4.
Prospective Comparison of Geriatric Assessment and Provider's Assessment of Older Adults With Metastatic Breast Cancer in the Community.
Oncologist
; 27(2): e133-e141, 2022 03 04.
Article
in English
| MEDLINE | ID: mdl-35641214
5.
Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer.
Breast Cancer Res Treat
; 196(1): 163-173, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-36028783
6.
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(6): 691-722, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35714673
7.
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).
Breast Cancer Res Treat
; 190(2): 265-275, 2021 Nov.
Article
in English
| MEDLINE | ID: mdl-34476645
8.
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.
J Natl Compr Canc Netw
; 19(5): 484-493, 2021 05 01.
Article
in English
| MEDLINE | ID: mdl-34794122
9.
Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Breast Cancer Res
; 22(1): 52, 2020 05 20.
Article
in English
| MEDLINE | ID: mdl-32434589
10.
A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Breast Cancer Res
; 22(1): 4, 2020 01 10.
Article
in English
| MEDLINE | ID: mdl-31924241
11.
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 18(4): 452-478, 2020 04.
Article
in English
| MEDLINE | ID: mdl-32259783
12.
Treatment delays from transfers of care and their impact on breast cancer quality measures.
Breast Cancer Res Treat
; 173(3): 603-617, 2019 Feb.
Article
in English
| MEDLINE | ID: mdl-30443881
13.
NCCN Guidelines Insights: Breast Cancer, Version 3.2018.
J Natl Compr Canc Netw
; 17(2): 118-126, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30787125
14.
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
N Engl J Med
; 372(10): 923-32, 2015 03 05.
Article
in English
| MEDLINE | ID: mdl-25738668
15.
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 16(3): 310-320, 2018 Mar.
Article
in English
| MEDLINE | ID: mdl-29523670
16.
A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104).
Breast Cancer Res Treat
; 165(2): 375-382, 2017 Sep.
Article
in English
| MEDLINE | ID: mdl-28623430
17.
NCCN Guidelines Insights: Breast Cancer, Version 1.2017.
J Natl Compr Canc Netw
; 15(4): 433-451, 2017 04.
Article
in English
| MEDLINE | ID: mdl-28404755
18.
Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient.
Breast Cancer Res Treat
; 160(1): 153-162, 2016 11.
Article
in English
| MEDLINE | ID: mdl-27640196
19.
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 14(3): 324-54, 2016 Mar.
Article
in English
| MEDLINE | ID: mdl-26957618
20.
Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary.
J Natl Compr Canc Netw
; 13(8): 947-52, 2015 Aug.
Article
in English
| MEDLINE | ID: mdl-26285240